20 May / 26
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor
04 May / 26
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to
08 Apr / 26
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25 th Annual Needham
06 Mar / 26
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to
Displaying 1 - 10 of 13
Popup Close
You’re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?
Return to the Absci website at any time by using the “Back” button on your web browser.

YES

NO

Popup Image